OPN1SW and cancer: Thus, employing BCP as an adjuvant agent in combinatorial treatments is likely a practical and effective way to mitigate the side effects of generic cancer chemotherapeutics and has the potential to take over the need for administering high doses of DOX or DDP in cancer treatments.